Lupin gets warning letter from USFDA for Somerset facility

14 Jun 2021 Evaluate

Lupin has received a warning letter from the United States Food and Drug Administration (USFDA) for the company’s Somerset, New Jersey facility. The USFDA had inspected the Lupin Somerset site from September 10, 2020 to November 5, 2020. The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.


Lupin Share Price

2089.65 -0.50 (-0.02%)
16-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1782.80
Dr. Reddys Lab 1279.00
Cipla 1500.00
Zydus Lifesciences 913.90
Lupin 2089.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×